Cargando…

Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies

Taking advantage of the immune system to exert an antitumor effect is currently a novel approach in cancer therapy. Adoptive transfer of T cells engineered to express chimeric antigen receptors (CARs) targeting a desired antigen has shown extraordinary antitumor activity, especially in refractory an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Jiali, Zhao, Lei, Zhang, Yuanyuan, Qin, Yun, Guan, Yuqi, Zhang, Tong, Liu, Chaohong, Zhou, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882288/ https://www.ncbi.nlm.nih.gov/pubmed/31824840 http://dx.doi.org/10.3389/fonc.2019.01237

Ejemplares similares

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Advances in Universal CAR-T Cell Therapy
por: Lin, Haolong, et al.
Publicado: (2021)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease
por: Zhang, Xiaomin, et al.
Publicado: (2023)

Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis from ovarian cancer
por: Domínguez-Prieto, Víctor, et al.
Publicado: (2023)

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
por: Quagliano, Anthony, et al.
Publicado: (2020)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future
por: Zhang, Zhengchao, et al.
Publicado: (2022)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

A Metabolism Toolbox for CAR T Therapy
por: Xu, Xuequn, et al.
Publicado: (2019)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
por: Lu, Yingjuan J., et al.
Publicado: (2019)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

CAR T Cell Therapy for Pediatric Brain Tumors
por: Patterson, John D., et al.
Publicado: (2020)

Strategies for Dodging the Obstacles in CAR T Cell Therapy
por: Safarzadeh Kozani, Pooria, et al.
Publicado: (2021)

B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma
por: Long, Cheng, et al.
Publicado: (2021)

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
por: Zhao, Yu, et al.
Publicado: (2022)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

Innovation in BCMA CAR-T therapy: Building beyond the Model T
por: Banerjee, Rahul, et al.
Publicado: (2022)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
por: Song, Moo-Kon, et al.
Publicado: (2019)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis
por: Grigor, Emma J M, et al.
Publicado: (2017)

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy
por: Li, Tongjuan, et al.
Publicado: (2019)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy
por: Guan, Yuqi, et al.
Publicado: (2021)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
por: Emran, Talha Bin, et al.
Publicado: (2022)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
por: Lu, Junjie, et al.
Publicado: (2023)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia
por: Zhou, Lanlan, et al.
Publicado: (2022)

CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap
por: Gatto, Lidia, et al.
Publicado: (2023)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ckmofg3c2ul0oa2pn6rbrbresn